الفهرس 
Introduction and aim of the workOnly 14 pages are availabe for public view
 |  | from | 16 |  |  |
| | | from | 16 | | |
Abstract
Lymphomas are a heterogeneous group of lymphoid disorders with clonal expansion of malignant lymphocytes. The current WHO classification takes into account clinical presentation, immunophenotype, cytogenetics, and molecular markers to differentiate the NHL from HD. Angiogenesis is essential for lymphoma growth, progression and metastasis which is stimulated by many pro-angiogenic factors and inflammatory cytokines. This study aims to measure the markers that define the progression of angiogenesis, inflammation and haemostatic states in patients with lymphoma before starting treatment and those under therapeutic procedures.
The study included 94 patients 54 diagnosed as NHL and 40 patients diagnosed as HD. The levels of; basic FGF, VEGF, PDGF-bb, Interleukin (IL)-1ß, IL- 6, IL-10, TNFα,MCP-1, G-CSF and Eotaxin in pre-treatment patients and in patients under chemo-radiotherapy were measured by Bio-Plex Pro assays. Twenty healthy donors were enrolled as controls.
The levels of all studied factors were significantly higher in pretreatment patients with lymphoma either NHL or HD compared to control subjects. Patients with NHL and HD under chemo-radiotherapy showed a significant decrease in the levels of studied markers compared to pre treatment patients. The levels of most markers measured in NHL and HD patients under treatment were insignificantly differs from their levels in control subjects. However, VEGF in NHL patients under treatment in spite of significantly lower than pretreatment patients but still significantly higher than controls. In HD patients under treatment, the levels of VEGF, IL-6, MCP-1 and Eotaxin were also still significantly higher than controls. All studied factors were higher in patients with progressive course of lymphoma than those with complete or partial remission. As regard hemostatic tests, there was a statistically insignificant increase in (PT) and (APTT) of both NHL and HD pre treatment patients compared to controls. APTT was significantly increased in under treatment lymphoma patients compared to controls while insignificant increase of PT.
Significant increase in the levels of studied angiogenic factors and inflammatory markers in pretreatment cases with NHL and HD indicate their roles in development of angiogenesis in lymphoma which has essential role in tumor growth and metastasis. After chemoradiotherapy these factors levels decreased inspite of insignificant decrease of some factors as VEGF that still higher than control which need more efforts to design a future effective antiangiogenic therapy and schedules that are customized to appropriate clinical settings.